TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
Brief Summary: Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are insufficient to optimize phosphorus control. Animal studies have shown niacinamide, a form of vitamin B, to reduce phosphate uptake by the rat small intestine. Our trial investigates the use of niacinamide, in addition to standard phosphorus lowering strategies, to reduce plasma phosphorus levels in peritoneal dialysis patients versus placebo.


Options:
A: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: SBR759A | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 4; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 5; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 4 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 5
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Niacinamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niacinamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): N/A
D: Arm Label: 900 mg Phosphate Diet-LC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lanthanum Carbonate, Other: 900 mg Phosphate Diet | Arm Label: Ad Libitum Diet-LC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lanthanum Carbonate, Other: Ad Libitum Diet | Arm Label: 900 mg Phosphate Diet-LC Placebo; Type: ACTIVE_COMPARATOR; Interventions: Other: 900 mg Phosphate Diet, Drug: LC Placebo | Arm Label: Ad Libitum Diet-LC Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LC Placebo, Other: Ad Libitum Diet | Intervention Type: DRUG; Name: Lanthanum Carbonate; Assigned to Arm(s): 900 mg Phosphate Diet-LC, Ad Libitum Diet-LC | Intervention Type: OTHER; Name: 900 mg Phosphate Diet; Assigned to Arm(s): 900 mg Phosphate Diet-LC, 900 mg Phosphate Diet-LC Placebo | Intervention Type: DRUG; Name: LC Placebo; Assigned to Arm(s): 900 mg Phosphate Diet-LC Placebo, Ad Libitum Diet-LC Placebo | Intervention Type: OTHER; Name: Ad Libitum Diet; Assigned to Arm(s): Ad Libitum Diet-LC, Ad Libitum Diet-LC Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
Brief Summary: Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are insufficient to optimize phosphorus control. Animal studies have shown niacinamide, a form of vitamin B, to reduce phosphate uptake by the rat small intestine. Our trial investigates the use of niacinamide, in addition to standard phosphorus lowering strategies, to reduce plasma phosphorus levels in peritoneal dialysis patients versus placebo.


Options:
A: Arm Label: Renal Function Group #1; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #2; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #3; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #4; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #5; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #6; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #7; Type: N/A; Interventions: N/A
B: Arm Label: Subjects with normal kidney function; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High calcium diet 2000 mg/day, Dietary Supplement: Low calcium diet, 800 mg/day | Arm Label: CKD late Stage 3 and Stage 4; Type: EXPERIMENTAL; Interventions: Dietary Supplement: High calcium diet 2000 mg/day, Dietary Supplement: Low calcium diet, 800 mg/day | Intervention Type: DIETARY_SUPPLEMENT; Name: High calcium diet 2000 mg/day; Assigned to Arm(s): CKD late Stage 3 and Stage 4, Subjects with normal kidney function | Intervention Type: DIETARY_SUPPLEMENT; Name: Low calcium diet, 800 mg/day; Assigned to Arm(s): CKD late Stage 3 and Stage 4, Subjects with normal kidney function
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Niacinamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niacinamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
Brief Summary: Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are insufficient to optimize phosphorus control. Animal studies have shown niacinamide, a form of vitamin B, to reduce phosphate uptake by the rat small intestine. Our trial investigates the use of niacinamide, in addition to standard phosphorus lowering strategies, to reduce plasma phosphorus levels in peritoneal dialysis patients versus placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Niacinamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niacinamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benfotiamine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benfotiamine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine
Brief Summary: In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'. Subsequently, MDA has received little attention until the introduction of artemisinin based combination therapy (ACT). The principle aim of MDA is to interrupt malaria transmission by clearing the population of sexual stage parasites, gametocytes, prior to the transmission season. Gametocytes are essential for propagation of the disease and elimination of gametocytes will result in a reduction in malaria transmission. As a consequence, a successful MDA will reduce the burden of disease in a population and is expected to have little influence on the development of protective immunity in areas of low transmission intensity. In Africa, only one large scale MDA study was conducted in the last 10 years. That study, conducted in The Gambia using sulphadoxine-pyrimethamine (SP) plus a single dose of artesunate (AS), failed to show a significant impact of MDA on malaria transmission. Possible reasons for this failure are the limited impact of the drug regimen (a single dose of AS) on malaria transmission, the incomplete coverage, the relatively high transmission intensity in the area and the migration of individuals between villages. Here, we propose to conduct an MDA study in an area of very low malaria transmission intensity in Tanzania. We use the highly active drug combination SP+AS (3 days) followed by a single dose of primaquine..


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: sulfadoxine /pyrimethamine plus amodiaquine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia
Brief Summary: The purpose of the study is to determine if the antibiotic ceftaroline is safe and effective in the treatment of community-acquired pneumonia in adults.


Options:
A: Arm Label: Ceftaroline fosamil for injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ceftriaxone, Drug: Placebo | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for injection | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone
B: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection, Drug: Clarithromycin | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Ceftriaxone, Drug: Placebo, Drug: Clarithromycin | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: IV Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Ceftaroline fosamil for Injection, IV Ceftriaxone
C: Arm Label: Levofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levofloxacin | Arm Label: CEM-101; Type: EXPERIMENTAL; Interventions: Drug: CEM-101 | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): Levofloxacin | Intervention Type: DRUG; Name: CEM-101; Assigned to Arm(s): CEM-101
D: Arm Label: Rapid result; Type: EXPERIMENTAL; Interventions: Procedure: Access to diagnostic test | Arm Label: Delayed result; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Access to diagnostic test; Assigned to Arm(s): Rapid result

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS
Brief Summary: Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Rebif® New Formulation (IFN-beta-1a, RNF); Type: EXPERIMENTAL; Interventions: Drug: Rebif® New Formulation (IFN-beta-1a, RNF) | Arm Label: Placebo/RNF; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Rebif® New Formulation (IFN-beta-1a, RNF) | Intervention Type: DRUG; Name: Rebif® New Formulation (IFN-beta-1a, RNF); Assigned to Arm(s): Rebif® New Formulation (IFN-beta-1a, RNF) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/RNF | Intervention Type: DRUG; Name: Rebif® New Formulation (IFN-beta-1a, RNF); Assigned to Arm(s): Placebo/RNF
B: Arm Label: Laquinimod; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS
Brief Summary: Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Laquinimod; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS
Brief Summary: Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Laquinimod; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
C: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo
D: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs. A Randomized Trial.
Brief Summary: The purpose of this study is to determine the effectiveness of maximal support of community pharmacies to implement a pharmaceutical care model for improving underprescription and treatment persistence regarding lipid-lowering medication in patients with cardiovascular disease.


Options:
A: Arm Label: Feedback; Type: EXPERIMENTAL; Interventions: Device: Feedback | Arm Label: Demonstration; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Feedback; Assigned to Arm(s): Feedback | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Demonstration
B: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Other: intensive implementation programme | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: control | Intervention Type: OTHER; Name: intensive implementation programme; Assigned to Arm(s): experimental | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmaceutical care program for antidepressant treatment | Intervention Type: BEHAVIORAL; Name: Pharmaceutical care program for antidepressant treatment; Assigned to Arm(s): Intervention Group
D: Intervention Type: BEHAVIORAL; Name: Home BP;secure messaging;pharmaceutical care;; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentered Randomized Controlled Trail to Test the Cost Effectiveness of Urodynamics in Women With Symptoms of Stress Urinary Incontinence in Whom Surgical Treatment is Considered
Brief Summary: To test the value of preoperatively performed urodynamics with regard to outcome of surgery for stress urinary incontinence (SUI) and to examine whether not performing urodynamics preoperatively is more cost effective than performing urodynamics preoperatively using the non-inferiority assumption.


Options:
A: Intervention Type: PROCEDURE; Name: Urodynamics; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: SS-RBX; Assigned to Arm(s): N/A
C: Arm Label: No UDS; Type: ACTIVE_COMPARATOR; Interventions: Other: Office evaluation | Arm Label: UDS; Type: ACTIVE_COMPARATOR; Interventions: Other: Office evaluation, Other: UDS | Intervention Type: OTHER; Name: Office evaluation; Assigned to Arm(s): No UDS, UDS | Intervention Type: OTHER; Name: UDS; Assigned to Arm(s): UDS
D: Arm Label: surgical therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: midureteral sling | Arm Label: individual management; Type: ACTIVE_COMPARATOR; Interventions: Other: surgical therapy or conservative | Intervention Type: PROCEDURE; Name: midureteral sling; Assigned to Arm(s): surgical therapy | Intervention Type: OTHER; Name: surgical therapy or conservative; Assigned to Arm(s): individual management

Answer: A